Voclosporin - Aurinia Pharmaceuticals
Alternative Names: trans-ISA 247; trans-R 1524; ISA(TX)247; ISA-247; ISAtx 247; ISATx247; LUPKYNIS; Orelvo; R-1524; VocleraLatest Information Update: 25 Nov 2024
At a glance
- Originator Isotechnika
- Developer Atrium Medical Corporation; Aurinia Pharmaceuticals; Isotechnika; Leiden University Medical Center; Otsuka Pharmaceutical; Paladin Labs
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies; Small molecules; Urologics; Vascular disorder therapies
- Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Lupus nephritis
- Phase II COVID 2019 infections; Focal segmental glomerulosclerosis
- No development reported Nephrotic syndrome; Renal transplant rejection
- Discontinued Coronary artery restenosis; Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 18 Nov 2024 Updated efficacy data from the phase III AURORA 1 trial in Lupus nephritis released by Aurinia Pharmaceuticals
- 14 Nov 2024 Efficacy data from the phase III AURORA 2 trial in Lupus nephritis presented at the ACR Convergence 2024 (ACR-2024)
- 24 Sep 2024 Registered for Lupus nephritis (Adjunctive treatment) in Japan (PO)